GENB
Generate Biomedicines, Inc.
NasdaqGSUSDEQUITY
Healthcare
DELAYED
Sell
-32/100
Last price
13.80
▼ 0.11 (0.79%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
13.91
Day high
14.19
Day low
13.55
Volume
1.17M
Market cap
$1.77B
P/E (TTM)
—
52W range
11.00 – 22.67
Trailing performance
Returnvs SPY
1W
-10.51%
-12.5%
1M
-15.80%
-17.0%
3M
-13.04%
-17.6%
6M
+16.65%
-1.5%
YTD
+9.09%
-5.2%
1Y
—
-16.4%
3Y
—
-82.3%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GENB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
18.03M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | ARNOLD FRANCES H PH.D. Director |
SELL | 1.00K | $16.00K | Direct |
| Mar 4, 26 | NALLY MICHAEL Chief Executive Officer |
BUY | 20.00K | $240.00K | Direct |
| Mar 2, 26 | AFEYAN NOUBAR BOGHOS Director and Beneficial Owner of more than 10% of a Class of Security |
— | 32.97M | — | Indirect |
| Mar 2, 26 | BANCEL STEPHANE J Director |
— | 724.16K | — | Indirect |
| Mar 2, 26 | NALLY MICHAEL Chief Executive Officer |
— | 658.33K | — | Indirect |
| Mar 2, 26 | AFEYAN NOUBAR BOGHOS Director and Beneficial Owner of more than 10% of a Class of Security |
BUY | 4.69M | $57.05M | Indirect |
| Mar 2, 26 | MENDILLO JANE L. Director |
BUY | 1.50K | $24.00K | Direct |
| Mar 2, 26 | SILVERS JASON M.D., J.D. President |
BUY | 2.00K | $32.00K | Indirect |
| Mar 2, 26 | GROUS BETH Officer |
BUY | 300 | $4.80K | Indirect |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
AFEYAN NOUBAR BOGHOS |
Director and Beneficial Owner of more than 10% of a Class of Security | — | Conversion of Exercise of derivative security |
ARNOLD FRANCES H PH.D. |
Director | 463.94K | Sale |
BANCEL STEPHANE J |
Director | — | Conversion of Exercise of derivative security |
GROUS BETH |
Officer | — | Purchase |
MENDILLO JANE L. |
Director | 1.50K | Purchase |
NALLY MICHAEL |
Chief Executive Officer | 2.89M | Purchase |
SILVERS JASON M.D., J.D. |
President | — | Purchase |
Fundamentals
Market cap$1.77B
Enterprise value$1.38B
Revenue (TTM)$26.48M
Gross profit$-213.80M
EBITDA$-249.55M
Net income$-268.67M
EPS (TTM)$-2.44
Free cash flow—
Total cash$457.42M
Total debt$62.63M
Book value / share$3.56
Shares outstanding128.35M
Float60.45M
Short % of float9.60%
Dividend yield0.00%
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E-6.05
PEG ratio—
Price / sales—
Price / book3.88
EV / revenue51.98
EV / EBITDA-5.52
Gross margin0.00%
Operating margin-1134.21%
Profit margin0.00%
Return on equity—
Return on assets—
Debt / equity13.73
Current ratio8.30
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Total revenue | $31.89M | $20.46M | +55.9% |
| Operating revenue | $31.89M | $20.46M | +55.9% |
| Research & development | $224.70M | $175.31M | +28.2% |
| Selling, general & admin | $42.26M | $42.09M | +0.4% |
| Total operating expense | $266.96M | $217.40M | +22.8% |
| Operating income | -$235.06M | -$196.94M | -19.4% |
| Net interest income | $12.53M | $16.00M | -21.7% |
| Pre-tax income | -$222.80M | -$181.17M | -23.0% |
| Tax provision | $163.00K | $212.00K | -23.1% |
| Net income | -$203.15M | -$173.77M | -16.9% |
| Net income to common | -$249.52M | -$213.78M | -16.7% |
| Basic EPS | -2.18 | -2.09 | -4.3% |
| Diluted EPS | -2.18 | -2.09 | -4.3% |
| EBIT | -$221.67M | -$179.05M | -23.8% |
| EBITDA | -$208.49M | -$163.71M | -27.4% |
| Basic shares | 102.31M | 102.31M | 0.0% |
| Diluted shares | 102.31M | 102.31M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Cash & equivalents | $121.65M | $176.27M | -31.0% |
| Cash & short-term investments | $221.50M | $393.63M | -43.7% |
| Accounts receivable | $0 | $308.00K | -100.0% |
| Total current assets | $234.37M | $407.49M | -42.5% |
| Property, plant & equipment | $89.01M | $101.07M | -11.9% |
| Total assets | $330.18M | $518.26M | -36.3% |
| Total current liabilities | $82.20M | $86.63M | -5.1% |
| Total debt | $68.53M | $76.97M | -11.0% |
| Total liabilities | $953.38M | $953.35M | +0.0% |
| Retained earnings | -$676.29M | -$473.14M | -42.9% |
| Shareholder equity | -$615.97M | -$434.52M | -41.8% |
| Working capital | $152.16M | $320.87M | -52.6% |
| Net tangible assets | -$615.97M | -$434.52M | -41.8% |
| Shares issued | 127.45M | 127.45M | 0.0% |
| Line item | 2025 | 2024 | YoY |
|---|---|---|---|
| Net income | -$222.97M | -$181.38M | -22.9% |
| Depreciation & amortisation | $13.18M | $15.35M | -14.1% |
| Stock-based compensation | $20.58M | $19.46M | +5.7% |
| Change in working capital | -$14.62M | $28.12M | -152.0% |
| Operating cash flow | -$200.62M | -$117.75M | -70.4% |
| Capital expenditure | -$3.51M | -$3.45M | -1.9% |
| Investing cash flow | $116.77M | -$57.73M | +302.3% |
| Financing cash flow | $28.06M | $91.33M | -69.3% |
| Free cash flow | -$204.13M | -$121.20M | -68.4% |
| End cash position | $126.04M | $181.83M | -30.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Total revenue | $6.31M | $7.22M | $10.13M | $8.82M | -12.6% |
| Operating revenue | $6.31M | $7.22M | $10.13M | $8.82M | -12.6% |
| Research & development | $64.33M | $57.81M | $59.73M | $46.83M | +11.3% |
| Selling, general & admin | $13.60M | $13.52M | $10.54M | $10.15M | +0.5% |
| Total operating expense | $77.93M | $71.34M | $70.28M | $56.97M | +9.2% |
| Operating income | -$71.61M | -$64.11M | -$60.15M | -$48.15M | -11.7% |
| Net interest income | $4.47M | $2.73M | $3.48M | $3.91M | +63.8% |
| Pre-tax income | -$67.20M | -$61.69M | -$56.70M | -$44.26M | -8.9% |
| Tax provision | $53.00K | $28.00K | $44.00K | $56.00K | +89.3% |
| Net income | -$67.25M | -$61.45M | -$52.43M | -$41.69M | -9.5% |
| Net income to common | -$67.25M | -$69.19M | -$64.02M | -$53.28M | +2.8% |
| Basic EPS | -0.52 | -1.07 | -0.63 | -0.52 | +51.4% |
| Diluted EPS | -0.52 | -1.07 | -0.63 | -0.52 | +51.4% |
| EBIT | -$67.05M | -$61.50M | -$56.39M | -$43.89M | -9.0% |
| EBITDA | -$63.82M | -$58.23M | -$53.07M | -$40.48M | -9.6% |
| Basic shares | 128.24M | 64.87M | 102.31M | 102.31M | +97.7% |
| Diluted shares | 128.24M | 64.87M | 102.31M | 102.31M | +97.7% |
| Line item | 2026-06-30 | 2026-03-31 | YoY |
|---|---|---|---|
| Cash & equivalents | $135.36M | $160.57M | -15.7% |
| Cash & short-term investments | $457.42M | $516.64M | -11.5% |
| Total current assets | $470.25M | $535.39M | -12.2% |
| Property, plant & equipment | $82.38M | $85.60M | -3.8% |
| Total assets | $561.69M | $625.74M | -10.2% |
| Total current liabilities | $56.64M | $58.39M | -3.0% |
| Total debt | $62.63M | $65.57M | -4.5% |
| Total liabilities | $105.64M | $110.94M | -4.8% |
| Retained earnings | -$804.99M | -$737.74M | -9.1% |
| Shareholder equity | $456.05M | $514.80M | -11.4% |
| Working capital | $413.62M | $477.00M | -13.3% |
| Net tangible assets | $456.05M | $514.80M | -11.4% |
| Shares issued | 128.27M | 128.19M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|
| Net income | -$67.25M | -$61.71M | -$56.74M | -$44.31M | -9.0% |
| Depreciation & amortisation | $3.22M | $3.27M | $3.32M | $3.41M | -1.5% |
| Stock-based compensation | $8.24M | $6.39M | $5.49M | $4.74M | +28.8% |
| Change in working capital | -$4.46M | -$30.65M | -$1.36M | -$17.44M | +85.5% |
| Operating cash flow | -$57.94M | -$80.39M | -$48.75M | -$53.18M | +27.9% |
| Capital expenditure | -$933.00K | -$3.78M | -$154.00K | -$751.00K | +75.3% |
| Investing cash flow | $33.31M | -$259.93M | -$17.07M | $75.53M | +112.8% |
| Financing cash flow | -$579.00K | $378.89M | -$263.00K | $20.56M | -100.2% |
| Free cash flow | -$58.88M | -$84.17M | -$48.91M | -$53.93M | +30.0% |
| End cash position | $139.39M | $164.61M | $158.66M | $224.75M | -15.3% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
12.50
-9.4% from spot
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
4
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
12.50
4 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.49 | -0.52 | -5.6% |
| Mar 2026 | -0.51 | -1.07 | -111.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.55 | 4 | $7.75M | — |
| Next quarter | -0.57 | 4 | $7.65M | — |
| Current year | -2.30 | 4 | $29.68M | — |
| Next year | -2.28 | 4 | $23.83M | -19.7% |
Analyst targets & ownership
Mean target$27.00
High target$30.00
Low target$22.00
Implied upside95.65%
Analyst count5
ConsensusSTRONG BUY
Strong buy / Buy2 / 4
Hold0
Sell / Strong sell0 / 0
Held by insiders14.05%
Held by institutions77.59%
Institutions holding125
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
14.82
-6.89% from price
SMA 20
15.59
-11.48% from price
SMA 50
15.49
-10.89% from price
SMA 100
14.90
-7.40% from price
SMA 200
—
—
EMA 12
14.84
-7.01% from price
EMA 26
15.35
-10.08% from price
EMA 50
15.35
-10.12% from price
RSI (14)
37.6
Neutral
MACD (12,26,9)
-0.51
Hist -0.32
ATR (14)
0.94
6.80% of price
Realised vol 30D
93.2%
Annualised
Bollinger upper
17.91
20, 2σ
Bollinger lower
13.27
20, 2σ
50 / 200 cross
—
—
Trend bias
—
—
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.33
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
93.2%
Annualised
Market vol 1Y
13.4%
SPY, annualised
Max drawdown 1Y
-32.8%
Peak to trough
Max drawdown 5Y
-32.8%
Peak to trough
ATR 14
0.94
6.80% of price
Beta (reported)
—
5Y monthly, from filing
Short interest
Shares short
7.18M
Prior 7.29M
Change vs prior
-1.5%
Shorts covering
% of float
9.60%
Normal
% of shares out
5.59%
Against total outstanding
Days to cover
4.7
Liquid
Float
60.45M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 5, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Sep 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 14, 26 | Morgan Stanley | MAINTAINED | Overweight | Overweight |
| May 8, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 13, 26 | HC Wainwright & Co. | INITIATED | — | Buy |
| Mar 24, 26 | Goldman Sachs | INITIATED | — | Buy |
| Mar 24, 26 | Morgan Stanley | INITIATED | — | Overweight |
| Mar 24, 26 | Piper Sandler | INITIATED | — | Overweight |
| Mar 24, 26 | Cantor Fitzgerald | INITIATED | — | Overweight |
| Mar 24, 26 | Guggenheim | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-26
Corporate Changes & Voting Matters
8-K · 2026-08-06
Periodic Financial Reports
10-Q · 2026-05-07
Corporate Changes & Voting Matters
8-K · 2026-03-02
Offering Registrations
S-8 · 2026-02-27
Trading Registrations
8-A12B · 2026-02-24
Offering Registrations
S-1/A · 2026-02-23
Offering Registrations
S-1/A · 2026-02-13
Headlines
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
GlobeNewswire · 6d ago
AI Could Eventually Crack Cancer and Drug Discovery, Says Arm CEO — But This Is What’s Holding It Back
Benzinga · 29d ago
Generate Biomedicines Inc. to Participate in September Investor Conferences
GlobeNewswire · 29d ago
How Nvidia’s Investment Juggernaut Can Jump from Big to Enormous
Barrons.com · 30d ago
Moderna raises $2.6B to support cancer work; FDA clears updated COVID vaccines
BioPharma Dive · 40d ago
EXCLUSIVE: Nvidia GPUs Are Essential—But They Won't Decide Who Wins AI Drug Discovery, Generate CTO Says
Benzinga · 41d ago
Cathie Wood Sends a $20 Million Signal on Broadcom Stock
GuruFocus.com · 41d ago
Generate Biomedicines (GENB) Stock Looks Pricey On Book Value Yet Strong On Returns
Simply Wall St. · 42d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.